Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a modified atkins diet help fight brain cancer?

NCT ID NCT02286167

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether a modified Atkins diet combined with intermittent fasting is possible and has any effect in 25 people with glioblastoma, an aggressive brain cancer. Participants followed the diet for several weeks while researchers checked if they could stick with it and measured changes in brain chemicals. The goal was to see if this diet approach is worth studying further as a supportive therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
modified Atkins-based intermittent fasting diet
What this could lead to
If successful, this diet approach could offer a supportive strategy to help manage glioblastoma by altering brain chemistry.
What could go wrong
This is a very small, early feasibility study with only 25 participants, so results may not apply widely. The diet is demanding and may be hard to follow long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

Nov 2014

Finished

Jul 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients must have a clinical and histopathologic diagnosis of GBM, have completed \>80% of prescribed concurrent radiation therapy and adjuvant temozolomide without CTCEA grade 3 or 4 toxicity, and be greater than 7 months from the time of completion of concurrent chemoradiotherapy. 2. Karnofsky performance status \>/= 60. 3. Patients must be at least 18 years of age. 4. Patients must be eligible to undergo a ketogenic or Atkins based diet according to baseline body mass index (BMI, see exclusion criteria), comorbid medical conditions (see exclusion criteria), and baseline laboratory assessment (see exclusion criteria). 5. Patients must be of appropriate mental capacities with sufficient social support so as to be able to complete required study activities (i.e. diet record, etc) and able to provide written informed consent. Exclusion Criteria: 1. Patients with a history of a metabolic disorder including documented defect in urea metabolism (including documented history of gout), carnitine deficiency (primary carnitine deficiency, carnitine palmitoyltransferase I or II deficiency, carnitine translocase deficiency), fatty acid metabolism, beta-oxidation defects, pyruvate carboxylase deficiency, mitochondrial function, porphyria, or nephrolithiasis. 2. Severe acute infection. 3. BMI \> 35.0 or BMI \< 20.0. 4. Active bowel obstruction, ileus, or active or remote pancreatitis. 5. Clinically significant heart failure (NYHA \>2), recent myocardial infarction, or symptomatic atrial fibrillation. 6. Clinically significant renal disease (creatinine \>2.0 mg/dL, urea \>100 mg/dL). 7. Clinically significant hepatic dysfunction (alanine or aspartate aminotransferase \>7 times the upper limit of normal). 8. Patients with insulin-dependent diabetes mellitus. 9. Conditions that may increase the risk of the diet or significantly reduce compliance (i.e. cognitive impairment, frank dementia, etc). 10. Other concurrent experimental therapies. 11. Milk allergy. 12. Treatment with the modified Atkins diet (MAD) for any cause within the 9 months prior to study enrollment 13. Patient inability to complete baseline screening 3-day diet record.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma multiforme are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Johns Hopkins Hospital

    Baltimore, Maryland, 21287, United States

  • Wake Forest School of Medicine

    Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.